Evolving impact of long-term survival results on metastatic melanoma treatment.

J Immunother Cancer · 2020 · PMC7549477 · PMID 33037115

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

82 In the phase II KEYNOTE-022 triplet study of dabrafenib plus trametinib with or without pembrolizumab, the difference in median PFS between the arms (16.9 vs 10.7 months) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.